Identifying and avoiding things that trigger symptoms in your individual case can help you to control your condition. Here are three easy ways to start tracking:

A new study has documented for the first time the clinical differences between subtype 1 (erythematotelangiectatic) rosacea – characterized by facial redness and, sometimes, visible blood vessels – and a condition with visible blood vessels from sun damage known as telangiectatic photoaging (TP), providing a clear picture of the differences between the two disorders and aiding in appropriate treatment.¹

In a recent study funded by the National Rosacea Society, Dr. Yoshikazu Uchida, research dermatologist at the University of California – San Francisco, and colleagues overcame a challenge that may lead to important advances in the treatment of rosacea.

As research continues to reveal the many ways the human microbiome may affect human health, the potential role of Demodex mites in rosacea has come into sharper focus with new technology and may point to new approaches in patient care, according to experts at a roundtable on the clinical implications of Demodex in rosacea.

While it has long been observed that rosacea may tend to run in families, the first genome-wide association study of rosacea may have discovered the genetic variants that are linked to this chronic skin disorder – as well as potential connections between rosacea and certain autoimmune disorders.¹